These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 11352966)
21. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer. Ruppert C; Ehrenforth S; Scharrer I; Halberstadt E Cancer Detect Prev; 1997; 21(5):452-9. PubMed ID: 9307848 [TBL] [Abstract][Full Text] [Related]
22. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Pedersen AN; Christensen IJ; Stephens RW; Briand P; Mouridsen HT; Danø K; Brünner N Cancer Res; 2000 Dec; 60(24):6927-34. PubMed ID: 11156392 [TBL] [Abstract][Full Text] [Related]
23. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Harbeck N; Schmitt M; Kates RE; Kiechle M; Zemzoum I; Jänicke F; Thomssen C Clin Breast Cancer; 2002 Aug; 3(3):196-200. PubMed ID: 12196277 [TBL] [Abstract][Full Text] [Related]
24. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993 [TBL] [Abstract][Full Text] [Related]
25. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677 [TBL] [Abstract][Full Text] [Related]
26. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients. De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A; Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353 [TBL] [Abstract][Full Text] [Related]
27. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667 [TBL] [Abstract][Full Text] [Related]
28. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Duffy MJ; Reilly D; O'Sullivan C; O'Higgins N; Fennelly JJ; Andreasen P Cancer Res; 1990 Nov; 50(21):6827-9. PubMed ID: 2119883 [TBL] [Abstract][Full Text] [Related]
29. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Meissauer A; Kramer MD; Schirrmacher V; Brunner G Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956 [TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. Harbeck N; Kates RE; Schmitt M J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823 [TBL] [Abstract][Full Text] [Related]
31. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer]. Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566 [TBL] [Abstract][Full Text] [Related]
32. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; Bolt-De Vries J; Benraad TJ; Foekens JA Br J Cancer; 1999 Apr; 80(1-2):286-94. PubMed ID: 10390010 [TBL] [Abstract][Full Text] [Related]
33. Impacts of aging and amyloid-β deposition on plasminogen activators and plasminogen activator inhibitor-1 in the Tg2576 mouse model of Alzheimer's disease. Bi Oh S; Suh N; Kim I; Lee JY Brain Res; 2015 Feb; 1597():159-67. PubMed ID: 25454795 [TBL] [Abstract][Full Text] [Related]
34. [The clinical prospects for the study of the plasminogen activation system in breast cancer]. Gershteĭn ES; Kushlinskiĭ NE Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126 [TBL] [Abstract][Full Text] [Related]
35. Urokinase and tissue plasminogen activators and their inhibitor PAI-1 in human tumors. Gershtein ES; Kushlinskii NE Bull Exp Biol Med; 2001 Jan; 131(1):67-72. PubMed ID: 11329087 [TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow. McWilliam N; Robbie L; Booth N; Bennett B Br J Haematol; 1998 Jun; 101(4):626-31. PubMed ID: 9674732 [TBL] [Abstract][Full Text] [Related]
37. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Duffy MJ; Duggan C Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage. Zhang X; Chaudhry A; Chintala SK Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409 [TBL] [Abstract][Full Text] [Related]
40. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]